{
  "url": "https://openlegislation.uk/eu-regulation-2007-129/annex-IV",
  "json_url": "https://openlegislation.uk/eu-regulation-2007-129/annex-IV.json",
  "legislation": "eur/2007/129",
  "legislation_title": "Council Regulation (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2007-129",
  "path": "annex/IV",
  "kind": "annex",
  "number": "IV",
  "heading": "List of pharmaceutical intermediates, i.e. compounds used for the manufacture of finished pharmaceutical products, to be withdrawn from the list of products receiving duty-free treatment included in Annex 6 to Regulation (EC) No 1549/2006",
  "text": "ID No\nCN code\nCAS RN\nName\n677\n2918 90 90\n157283-68-6\nisopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(E)-(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl}cyclopentyl]hept-5-enoate\ntravoprost (INN)\n603\n2924 29 95\n112522-64-2\n4-acetamido-2'-aminobenzanilide\ntacedinaline (INN)\n69\n2924 29 95\n166518-60-1\nN-[(2,6-diisopropylphenoxy)sulfonyl]-2-(2,4,6-triisopropylphenyl)acetamide\navasimibe (INN)\n441\n2928 00 90\n53016-31-2\n13-ethyl-17-alpha-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one oxime\nnorelgestromin (INN)\n833\n2930 90 30\n583-91-5\n2-hydroxy-4-(methylthio)butyric acid\ndesmeninol (INN)\n273\n2932 99 70\n114870-03-0\nmethyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1,4)-O-beta-D-glucopyranuronosyl-(1,4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1,4)-O-2-O-sulfo-alpha-L-idopyranuronosyl-(1,4)-2-deoxy-2-(sulfoamino)-6-(hydrogen sulfate)-alpha-D-glucopyranoside, decasodium salt\nfondaparinux sodium (INN)\n627\n2933 39 99\n75970-99-9\n[1-(4-fluorobenzyl)-1H-benzimidazol-2-yl](4-piperidyl)amine\ntecastemizole (INN)\n159\n2933 39 99\n100643-71-8\n8-chloro-11-(4-piperidylidene)-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridine\ndesloratadine (INN)\n549\n2933 39 99\n168273-06-1\n5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidino-1H-pyrazole-3-carboxamide\nrimonabant (INN)\n380\n2933 39 99\n193275-84-2\n4-{4-[(11R)-3,10-dibromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperidinocarbonylmethyl}piperidine-1-carboxamide\nlonafarnib (INN)\n397\n2933 49 90\n146362-70-1\n2-{[1-(7-chloro-4-quinolyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonylamino}adamantane-2-carboxylic acid\nmeclinertant (INN)\n641\n2933 59 95\n147127-20-6\n(R)-[2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methylphosphonic acid\ntenofovir (INN)\n205\n2933 59 95\n149950-60-7\n6-benzyl-1-(ethoxymethyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione\nemivirine (INN)\n511\n2933 59 95\n153537-73-6\n(S)-2-(4-{[(2,7-dimethyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl](prop-2-ynyl)amino}-2-fluorobenzamido)-4-(1H-tetrazol-5-yl)butyric acid\nplevitrexed (INN)\n686\n2934 99 90\n112984-60-8\n(+-)-6-fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid\nulifloxacin (INN)\n33\n2934 99 90\n145514-04-1\n(2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-1,3-dioxolan-2-ylmethanol\namdoxovir (INN)\n513\n2934 99 90\n171228-49-2\n4-[4-(4-{4-[(3R,5R)-5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-ylmethyloxy]phenyl}piperazin-1-yl)phenyl]-1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,2,4-triazol-5(4H)-one\nposaconazole (INN)\n293\n2934 99 90\n184475-35-2\n(3-chloro-4-fluorophenyl)[7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl]amine\ngefitinib (INN)\n539\n2935 00 90\n150375-75-0\nN'-{(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-3-hydroxy-2,3-dihydro-1H-indol-2-ylcarbonyl}-L-prolinamide\nrelcovaptan (INN)\n39\n2935 00 90\n161814-49-9\n(3S)-tetrahydrofuran-3-yl (1S,2R)-3-[(4-aminophenylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate\namprenavir (INN)\n115\n2935 00 90\n169590-42-5\n4-[5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide\ncelecoxib (INN)\n654\n2935 00 90\n180200-68-4\n4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide\ntilmacoxib (INN)\n690\n2935 00 90\n181695-72-7\n4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide\nvaldecoxib (INN)\n520\n2935 00 90\n192329-42-3\n(S)-N-hydroxy-2,2-dimethyl-4-[4-(4-pyridyloxy)phenylsulfonyl]-1,4-thiazinane-3-carboxamide\nprinomastat (INN)\n364\n3002 10 95\n193700-51-5\nSC-70935\nleridistim (INN)",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2007/129/annex/IV",
    "retrieved_at": "2026-11-01T14:53:05.945898+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}